RICARDO ROMITI
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/53 - Laboratório de Micologia, Hospital das Clínicas, Faculdade de Medicina
LIM/50 - Laboratório de Patologia das Moléstias Infecciosas, Hospital das Clínicas, Faculdade de Medicina
LIM/53 - Laboratório de Micologia, Hospital das Clínicas, Faculdade de Medicina
LIM/50 - Laboratório de Patologia das Moléstias Infecciosas, Hospital das Clínicas, Faculdade de Medicina
9 resultados
Resultados de Busca
Agora exibindo 1 - 9 de 9
- Extensive cutaneous involvement by dermatomyositis: Report of six cases and review of the literature(2020) MIYASHIRO, Denis; ARNONE, Marcelo; FERREIRA, Paula Silva; ROMITI, Ricardo; SANCHES, Jose Antonio
- Generalized pustular psoriasis (von Zumbusch)(2022) ROMITI, Ricardo; HIRAYAMA, Andre Luis da Silva; ARNONE, Marcelo; MAGALHAES, Renata FerreiraGeneralized pustular psoriasis (von Zumbusch) is a rare and acute eruption characterized by multiple sterile pustules over an erythematous and edematous background, eventually associated with psoriasis vulgaris. Classically, it manifests as a potentially severe systemic picture and demands prompt diagnosis and intervention. The duration of each flare-up and intervals between the pustular episodes is extremely variable. Recently, genetic abnormalities have been identified mainly in the familial and early variants of this disease. The therapeutic arsenal is limited; however, new drugs being evaluated aim to control both pustular flare-ups and disease recurrences. (C) 2021 Sociedade Brasileira de Dermatologia.
- Therapeutic response and survival time of immunobiologicals in patients with moderate to severe psoriasis(2022) MOTA, Cynthia Cristina Ferreira; ROMITI, Ricardo; ARNONE, Marcelo; HIRAYAMA, Andre Luis da Silva; TAKAHASHI, Maria Denise Fonseca
- Diagnostic and therapeutic guidelines for plaque psoriasis - Brazilian Society of Dermatology(2019) ARNONE, Marcelo; TAKAHASHI, Maria Denise Fonseca; CARVALHO, Andre Vicente Esteves de; BERNARDO, Wanderley Marques; BRESSAN, Aline Lopes; RAMOS, Andrea Machado Coelho; TERENA, Aripuana Coberio; SOUZA, Cacilda da Silva; NUNES, Daniel Holthausen; BORTOLETTO, Maria Cecilia de Carvalho; OLIVEIRA, Maria de Fatima Santos Paim de; NEFFA, Jane Marcy; FIERI, Luciana Cristina; AZULAY-ABULAFIA, Luna; FELIX, Paulo Antonio Oldani; MAGALHAES, Renata Ferreira; ROMITIL, Ricardo; JAIME, Tatiana JerezPsoriasis is a chronic inflammatory disease that affects 1.3% of the Brazilian population. The most common clinical manifestations are erythematous, scaling lesions that affect both genders and can occur on any anatomical site, preferentially involving the knees, elbows, scalp and genitals. Besides the impact on the quality of life, the systemic nature of the disease makes psoriasis an independent risk factor for cardiovascular disease, especially in young patients with severe disease. By an initiative of the Brazilian Society of Dermatology, dermatologists with renowned clinical experience in the management of psoriasis were invited to form a work group that, in a partnership with the Brazilian Medical Association, dedicated themselves to create the Plaque Psoriasis Diagnostic and Treatment Guidelines. The relevant issues for the diagnosis (evaluation of severity and comorbidities) and treatment of plaque psoriasis were defined. The issues generated a search strategy in the Medline-PubMed database up to July 2018. Subsequently, the answers to the questions of the recommendations were devised, and each reference selected presented the respective level of recommendation and strength of scientific evidence. The final recommendations for making up the final text were worded by the coordinators.
- Impact of Inflammatory Immune Dysfunction in Psoriasis Patients at Risk for COVID-19(2021) YENDO, Tatiana Mina; SATO, Maria Notomi; BRANCO, Anna Claudia Calvielli Castelo; PIETROBON, Anna Julia; TEIXEIRA, Franciane Mouradian Emidio; RAMOS, Yasmim alefe Leuzzi; ALBERCA, Ricardo Wesley; VALENCIO, Cesar Giudice; ARRUDA, Vivian Nunes; ROMITI, Ricardo; ARNONE, Marcelo; HIRAYAMA, Andre Luis da Silva; DUARTE, Alberto Jose da Silva; AOKI, Valeria; ORFALI, Raquel LeaoPsoriasis is an immune-mediated dermatosis usually associated with comorbidities. Treatment varies from topicals to systemic drugs and data on susceptibility to viral infections in psoriatic patients are scarce. The objectives of this study were to analyze psoriatic patients on different therapies who were at risk for COVID-19 for seroprevalence of SARS-COV-2, pro-inflammatory cytokine profile, comorbidities and outcomes in order to unveil the immunological mechanisms involved in the anti-viral response in patients with psoriasis. Seventy-five patients with psoriasis were divided according to treatment: immunobiologics, methotrexate, topicals and acitretin. Twenty healthy controls were included. Plasma samples were collected for: IgG SARS-COV-2 (ELISA); IL-27, IL-29 and IL-18 (ELISA); and IL-1 beta, IL-17A, IL-6 and TNF (cytometric array). Seropositivity for SARS-COV-2 was detected in 24 out of 75 psoriasis patients and did not relate to COVID-19 symptoms and/or hospitalization, despite associated comorbidities. Psoriasis patients who were asymptomatic for SARS-COV-2 exhibited immune imbalance with high levels of IL-18, IL-17A and IL-6, and low levels of IL-27 compared to healthy controls. Psoriasis groups showed significant increased cytokine levels only in the group with immunobiologics. Despite immune deviations and lower IL-27, which has a potential antiviral impact, psoriatic patients did not exhibit complications related to COVID-19. An understanding of this kind of proinflammatory profile of psoriatic patients and of the lack of severe outcomes for COVID-19 is essential to establish novel therapeutic approaches and preventive measures, including with regard to the concomitance of viral infections.
- One-year prospective nerve conduction study of thalidomide neuropathy in lupus erythematosus: Incidence, coasting effect and drug plasma levels(2021) YUKI, Emily Figueiredo Neves; SOARES, Renata; KUPA, Leonard de Vinci Kanda; HEISE, Carlos Otto; AIKAWA, Nadia Emi; ARNONE, Marcelo; ROMITI, Ricardo; PEDROSA, Tatiana do Nascimento; SILVA, Clovis Artur Almeida da; BONFA, Eloisa; PASOTO, Sandra GofinetBackground Few prospective studies in cutaneous and systemic lupus erythematosus (CLE/SLE) assessed thalidomide-induced peripheral neuropathy (TiPN) incidence/reversibility, and most have not excluded confounding causes neither monitored thalidomide plasma levels. Objectives To evaluate TiPN incidence/reversibility, coasting effect and its association with thalidomide plasma levels in CLE/SLE. Methods One-year prospective study of thalidomide in 20 CLE/SLE patients without pregnancy potential, with normal nerve conduction study (NCS), and excluded other PN causes. Thalidomide levels were determined by high-performance liquid chromatography/tandem mass spectrometry. Results Twelve patients (60%) developed TiPN: 33.3% were symptomatic and 66.6% asymptomatic. Half of this latter group developed coasting effect (TiPN symptoms 1-3 months after drug withdrawal). The main predictive factors for TiPN were treatment duration >= 6 months (p = 0.025) and cumulative dose (p = 0.023). No difference in plasma thalidomide levels between patients with/without TiPN was observed (p = 0.464). After drug withdrawal, 75% symptomatic TiPN patients improved their symptoms. Seven TiPN patients underwent an additional NCS after drug withdrawal: 42.8% worsened NCS, 14.2% was stable, and 42.8% had improved NCS. Conclusion Our data provides novel evidence of coasting effect in half of asymptomatic patients with TiPN. The irreversible nature of this lesion in 25% of TiPN patients reinforces the relevance of early NCS monitoring, and suggests thalidomide use solely as a bridge for other effective therapy for refractory cutaneous lupus patients.
bookPart Eritema e descamação: dermatite seborreica e psoríase(2022) ARNONE, Marcelo; ROMITI, Ricardo; MARAGNO, LucianabookPart Eritrodermia(2022) ARNONE, Marcelo; ROMITI, Ricardo- Guselkumab: widened action in psoriatic disease(2021) ARNONE, Marcelo; CARVALHO, Andre Vicente Esteves de; FABRICIO, Lincoln Zambaldi; ROMITI, Ricardo